Skip to main content
Critical Care logoLink to Critical Care
letter
. 2015 Nov 17;19:392. doi: 10.1186/s13054-015-1104-5

Is neutrophil gelatinase-associated lipocalin unaffected by convective continuous renal replacement therapy? Definitely … maybe

Patrick M Honore 1,, Rita Jacobs 1, Inne Hendrickx 1, Elisabeth De Waele 1, Viola Van Gorp 1, Herbert D Spapen 1
PMCID: PMC4647326  PMID: 26573621

Two recent studies published in Critical Care reported that plasma [1] and urinary [2] levels of neutrophil gelatinase-associated lipocalin (NGAL), an important biomarker for prediction and diagnosis of acute kidney injury, were not affected by continuous renal replacement therapy (CRRT).

The investigators assessed NGAL elimination during continuous venovenous hemofiltration [1] and hemodiafiltration [2] using respectively a cellulose triacetate [1] and a polysulfone [2] membrane filter. Of note is that these filters both have notoriously low adsorption capacity [3]. Recently, the proinflammatory high-mobility group box 1 protein, a cytokine with a molecular weight approximating that of NGAL, was also found to be unaffected by convective CRRT. However, it was significantly (up to 90 %!) cleared from the circulation when highly adsorptive membranes (i.e., surface-treated acrylonitrile 69 and polymethylmethacrylate) were used [4].

These membranes are increasingly applied for hemofiltration in critically ill patients [4]. Thus, it is imperative to evaluate NGAL clearance during convective CRRT performed with highly adsorptive membranes before definitively accepting that CRRT leaves the sensitivity of this biomarker intact.

Abbreviations

CRRT

Continuous renal replacement therapy

NGAL

Neutrophil gelatinase-associated lipocalin

Footnotes

See related research by Schilder et al., http://www.ccforum.com/content/18/2/R78; and Vasileiadis et al., http://www.ccforum.com/content/19/1/140

Competing interests

The authors declare that they have no competing interests.

Contributor Information

Patrick M. Honore, Phone: 003224749097, Email: Patrick.Honore@az.vub.ac.be

Rita Jacobs, Email: Rita.Jacobs@uzbrussel.be.

Inne Hendrickx, Email: Inne.Hendrickx@uzbrussel.be.

Elisabeth De Waele, Email: Elisabeth.Dewaele@uzbrussel.be.

Viola Van Gorp, Email: Viola.Vangorp@uzbrussel.be.

Herbert D. Spapen, Email: Herbert.Spapen@uzbrussel.be

References

  • 1.Schilder L, Nurmohamed SA, ter Wee PM, Paauw NJ, Girbes AR, Beishuizen A, et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Crit Care. 2014;18:R78. doi: 10.1186/cc13838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Vasileiadis I, Pipili C, Nanas S. Continuous renal replacement therapy in critically ill patients does not affect urinary neutrophil gelatinase-associated lipocalin levels. Crit Care. 2015;19:140. doi: 10.1186/s13054-015-0834-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, et al. Newly designed CRRT membranes for sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013;59:99–106. doi: 10.1097/MAT.0b013e3182816a75. [DOI] [PubMed] [Google Scholar]
  • 4.Yumoto M, Nishida O, Moriyama K, Shimomura Y, Nakamura T, Kuriyama N, et al. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial. 2011;15:385–93. doi: 10.1111/j.1744-9987.2011.00971.x. [DOI] [PubMed] [Google Scholar]

Articles from Critical Care are provided here courtesy of BMC

RESOURCES